Price | 6003€+ Login to see price |
Organism | Human |
Product Type | Organoid + Cytotoxic T cell |
Tissue | Adaptive |
Disease | – |
Applications
Cancer Organoid
Colorectal Cancer
Non-Small Cell Lung Cancer
Pancreatic Cancer
Breast Cancer
Cholangiocarcinoma
Gastric Cancer
Ovarian Cancer
PD L1 binds to PD 1 and inhibits T cell kiling of tumor cell
Blocking PD L1 or PD 1 allows T cell kiling of tumor cell
High Responder to control
Low Responder to control
Our cutting-edge platform brings approach in drug development, empowering clinicians and researchers to transcend beyond the binary classification of responders versus non-responders.
It facilitates a deeper examination of patient-specific responses to approved control drugs at various concentrations.
This technology illuminates the intricate interplay between genetic, regional, and environmental factors and their impact on drug efficacy, providing a path to address the pressing unmet needs in before clinical trail.
This example showcases the potential utility of our platform in identifying optimal partners for combination therapy with Immune Checkpoint Inhibitors (ICIs).
His suggests that Combination B could be a more effective strategy in enhancing the efficacy of ICIs.
This platform is designed to facilitate such discoveries, offering a clear pathway to improve clinical outcomes through strategic drug pairing.
